Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
61.17
+0.32 (0.53%)
Oct 28, 2025, 12:09 PM EDT - Market open
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 18 analysts that cover Kymera Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $65.56, which forecasts a 7.18% increase in the stock price over the next year. The lowest target is $52 and the highest is $81.
Price Target: $65.56 (+7.18%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 8 | 9 |
| Buy | 6 | 7 | 7 | 7 | 8 | 9 |
| Hold | 4 | 2 | 2 | 2 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 17 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $59 → $75 | Strong Buy | Maintains | $59 → $75 | +22.61% | Oct 22, 2025 |
| Mizuho | Mizuho | Buy Initiates $81 | Buy | Initiates | $81 | +32.42% | Oct 21, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $60 → $80 | Strong Buy | Maintains | $60 → $80 | +30.78% | Oct 17, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $53 → $63 | Buy | Maintains | $53 → $63 | +2.99% | Oct 1, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $53 → $68 | Strong Buy | Maintains | $53 → $68 | +11.17% | Sep 30, 2025 |
Financial Forecast
Revenue This Year
75.73M
from 47.07M
Increased by 60.88%
Revenue Next Year
59.88M
from 75.73M
Decreased by -20.93%
EPS This Year
-3.47
from -2.98
EPS Next Year
-4.09
from -3.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 154.3M | 141.8M | |||
| Avg | 75.7M | 59.9M | |||
| Low | 42.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 227.9% | 87.2% | |||
| Avg | 60.9% | -20.9% | |||
| Low | -9.2% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.60 | -2.78 | |||
| Avg | -3.47 | -4.09 | |||
| Low | -3.84 | -6.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.